Literature DB >> 12601107

HLA-related subpopulations of MS in Japanese with and without oligoclonal IgG bands. Human leukocyte antigen.

S Kikuchi1, T Fukazawa, M Niino, I Yabe, R Miyagishi, T Hamada, S A Hashimoto, K Tashiro.   

Abstract

BACKGROUND: Oligoclonal IgG bands (OCB) are present in most patients with MS in Western countries; however, in Japanese MS patients, the OCB-positive rate is not as high. A relationship between immunogenetic backgrounds, namely, human leukocyte antigen (HLA) DR2 and DR4 positivity, and OCB production in MS patients from Hokkaido, the northernmost island of Japan, has been previously suggested by the authors.
OBJECTIVES: To investigate the role of OCB in Japanese MS and to verify the interaction between immunogenetic backgrounds and OCB positivity.
METHODS: OCB, DR2(15), and DR4 positivity were studied in 45 patients with newly diagnosed MS. In addition to confirming the authors' previous findings, the clinical and demographic features, MRI findings, OCB positivity, and DRB1*15 and DRB1*04 polymorphisms of an expanded data set of 99 MS patients were investigated by using multivariate analysis. Patients with opticospinal MS (OS-MS) were excluded from this study.
RESULTS: A relatively low OCB-positive rate (53.3%), HLA-DR15 association with OCB-positive MS (p = 0.0044), and DR4 association with OCB-negative MS (p = 0.0410) were confirmed. DR15 was not associated with OCB-negative MS. Demographic features, disease course, and disability were similar in the OCB-negative and OCB-positive group, whereas there was a preponderance of women in the OCB-positive group. An independent negative association of DRB1*0405 (p = 0.0021, adjusted odds ratio = 0.21) with OCB positivity was found.
CONCLUSIONS: MS is heterogeneous in its association with HLA alleles, and based on the immunogenetic differences, the MS patients in this population include at least two HLA-related subpopulations with and without OCB.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12601107     DOI: 10.1212/01.wnl.0000048202.09147.9e

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  14 in total

1.  Genetic variants are major determinants of CSF antibody levels in multiple sclerosis.

Authors:  An Goris; Ine Pauwels; Marte W Gustavsen; Brechtje van Son; Kelly Hilven; Steffan D Bos; Elisabeth Gulowsen Celius; Pål Berg-Hansen; Jan Aarseth; Kjell-Morten Myhr; Sandra D'Alfonso; Nadia Barizzone; Maurizio A Leone; Filippo Martinelli Boneschi; Melissa Sorosina; Giuseppe Liberatore; Ingrid Kockum; Tomas Olsson; Jan Hillert; Lars Alfredsson; Sahl Khalid Bedri; Bernhard Hemmer; Dorothea Buck; Achim Berthele; Benjamin Knier; Viola Biberacher; Vincent van Pesch; Christian Sindic; Annette Bang Oturai; Helle Bach Søndergaard; Finn Sellebjerg; Poul Erik H Jensen; Manuel Comabella; Xavier Montalban; Jennifer Pérez-Boza; Sunny Malhotra; Jeannette Lechner-Scott; Simon Broadley; Mark Slee; Bruce Taylor; Allan G Kermode; Pierre-Antoine Gourraud; Stephen J Sawcer; Bettina Kullle Andreassen; Bénédicte Dubois; Hanne F Harbo
Journal:  Brain       Date:  2015-01-22       Impact factor: 13.501

2.  Association of HLA Genetic Risk Burden With Disease Phenotypes in Multiple Sclerosis.

Authors:  Noriko Isobe; Anisha Keshavan; Pierre-Antoine Gourraud; Alyssa H Zhu; Esha Datta; Regina Schlaeger; Stacy J Caillier; Adam Santaniello; Antoine Lizée; Daniel S Himmelstein; Sergio E Baranzini; Jill Hollenbach; Bruce A C Cree; Stephen L Hauser; Jorge R Oksenberg; Roland G Henry
Journal:  JAMA Neurol       Date:  2016-07-01       Impact factor: 18.302

3.  Clinical and cognitive implications of cerebrospinal fluid oligoclonal bands in multiple sclerosis patients.

Authors:  Maria Anagnostouli; Foteini Christidi; Ioannis Zalonis; Chryssoula Nikolaou; Dimitrios Lyrakos; Nikolaos Triantafyllou; Ioannis Evdokimidis; Constantinos Kilidireas
Journal:  Neurol Sci       Date:  2015-07-01       Impact factor: 3.307

Review 4.  Biomarkers in Multiple Sclerosis.

Authors:  Anu Paul; Manuel Comabella; Roopali Gandhi
Journal:  Cold Spring Harb Perspect Med       Date:  2019-03-01       Impact factor: 6.915

5.  CSF pleocytosis and expansion of spinal lesions in Japanese multiple sclerosis with special reference to the new diagnostic criteria.

Authors:  Toshiyuki Fukazawa; Seiji Kikuchi; Ryuji Miyagishi; Yusei Miyazaki; Hikoaki Fukaura; Ichiro Yabe; Takeshi Hamada; Kunio Tashiro; Hidenao Sasaki
Journal:  J Neurol       Date:  2005-03-06       Impact factor: 4.849

6.  Cerebrospinal fluid oligoclonal immunoglobulin gamma bands and long-term disability progression in multiple sclerosis: a retrospective cohort study.

Authors:  Virginija Danylaité Karrenbauer; Sahl Khalid Bedri; Jan Hillert; Ali Manouchehrinia
Journal:  Sci Rep       Date:  2021-07-22       Impact factor: 4.379

7.  Progress in multiple sclerosis genetics.

Authors:  An Goris; Ine Pauwels; Bénédicte Dubois
Journal:  Curr Genomics       Date:  2012-12       Impact factor: 2.236

8.  Biomarkers in Multiple Sclerosis: An Up-to-Date Overview.

Authors:  Serafeim Katsavos; Maria Anagnostouli
Journal:  Mult Scler Int       Date:  2013-01-22

9.  Oligoclonal band status in Scandinavian multiple sclerosis patients is associated with specific genetic risk alleles.

Authors:  Inger-Lise Mero; Marte W Gustavsen; Hanne S Sæther; Siri T Flåm; Pål Berg-Hansen; Helle B Søndergaard; Poul Erik H Jensen; Tone Berge; Anja Bjølgerud; Aslaug Muggerud; Jan H Aarseth; Kjell-Morten Myhr; Elisabeth G Celius; Finn Sellebjerg; Jan Hillert; Lars Alfredsson; Tomas Olsson; Annette Bang Oturai; Ingrid Kockum; Benedicte A Lie; Bettina Kulle Andreassen; Hanne F Harbo
Journal:  PLoS One       Date:  2013-03-05       Impact factor: 3.240

10.  Genetic and infectious profiles of Japanese multiple sclerosis patients.

Authors:  Satoshi Yoshimura; Noriko Isobe; Tomomi Yonekawa; Takuya Matsushita; Katsuhisa Masaki; Shinya Sato; Yuji Kawano; Ken Yamamoto; Jun-ichi Kira
Journal:  PLoS One       Date:  2012-11-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.